Comparison of organ uptake and disappearance half-time of human epidermal growth factor and insulin

Konturek, S J; Pawlik, Wiesław W.; Mysh, W.; Gustaw, P; Sendur, R; Mikoś, E; Bielański, Władysław

doi:10.1016/0167-0115(90)90054-z

Cited by 17 publications

(14 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, these molecules have high instability and very short biological half time and can be enzymatically digested or deactivated while in physiological fluids [87, 88]. Besides, growth factors or drugs need to reach specific location to be effective; thus, their systemic introduction is not a viable way to control their concentration in specific target areas [89].…”

Section: Cell Microenvironment Control Via Delivery Of Soluble Biomentioning

confidence: 99%

Cell Microenvironment Engineering and Monitoring for Tissue Engineering and Regenerative Medicine: The Recent Advances

Barthès

Özçelik

Hindié

et al. 2014

BioMed Research International

194

129

View full text Add to dashboard Cite

In tissue engineering and regenerative medicine, the conditions in the immediate vicinity of the cells have a direct effect on cells' behaviour and subsequently on clinical outcomes. Physical, chemical, and biological control of cell microenvironment are of crucial importance for the ability to direct and control cell behaviour in 3-dimensional tissue engineering scaffolds spatially and temporally. In this review, we will focus on the different aspects of cell microenvironment such as surface micro-, nanotopography, extracellular matrix composition and distribution, controlled release of soluble factors, and mechanical stress/strain conditions and how these aspects and their interactions can be used to achieve a higher degree of control over cellular activities. The effect of these parameters on the cellular behaviour within tissue engineering context is discussed and how these parameters are used to develop engineered tissues is elaborated. Also, recent techniques developed for the monitoring of the cell microenvironment in vitro and in vivo are reviewed, together with recent tissue engineering applications where the control of cell microenvironment has been exploited. Cell microenvironment engineering and monitoring are crucial parts of tissue engineering efforts and systems which utilize different components of the cell microenvironment simultaneously can provide more functional engineered tissues in the near future.

show abstract

Section: Cell Microenvironment Control Via Delivery Of Soluble Biomentioning

confidence: 99%

Cell Microenvironment Engineering and Monitoring for Tissue Engineering and Regenerative Medicine: The Recent Advances

Barthès

Özçelik

Hindié

et al. 2014

BioMed Research International

194

129

View full text Add to dashboard Cite

show abstract

“…However, the dose used in this study was selected to result in limited body growth retardation yet be efficacious in inducing early eyelid opening [32,8]. Single injections of EGF once a day do not totally replete the EGF deficiency since the serum half-life for EGF is about 7 min [33]. However, this EGF treatment was sufficient to induce renal and extrarenal changes in neonatal bpk mice with PKD.…”

Section: Discussionmentioning

confidence: 99%

Renal dysfunction but not cystic change is ameliorated by neonatal epidermal growth factor in bpk mice

Nakanishi

Gattone

Sweeney

et al. 2001

Pediatric Nephrology

View full text Add to dashboard Cite

BALB/c mice homozygous for the bpk gene exhibit a form of autosomal recessive (AR) polycystic kidney disease (PKD) with massive collecting duct cysts, common bile duct dilation and chaotic intrahepatic bile ducts/portal triads. The combined renal and biliary pathology mimics much of the pathology seen in human ARPKD. Murine models of ARPKD generally have a reduced renal expression of epidermal growth factor (EGF) and an increased expression of EGF receptors (EGF-R). However, the role that EGF and EGF-R play in the progression of PKD has been unclear. Evidence from various model systems/ages of treatment produces conflicting results. Treating neonatal C57BL/6J-cpk mice with EGF ameliorates the renal pathology and dysfunction while treating 2- and 3-week-old bpk mice with an EGF-receptor tyrosine kinase inhibitor also ameliorates ARPKD. Therefore, to determine whether neonatal EGF treatment would accelerate or inhibit the progression of the PKD in bpk mice, we administered exogenous EGF (1 microgram/g body weight subcutaneously) daily from postnatal days 3-9 (a critical period for tubule maturation). Neonatal EGF treatment but not sham treatment retarded the development of azotemia and common bile duct dilation and the chaotic hepatic triad changes in cystic mice. However, EGF treatment neither reduced the severity of the renal cystic pathology nor reduced the degree of cystic enlargement of the kidneys. Cystic mice treated past 9 days of age died prior to their scheduled termination at 21 days of age. The role of EGF in the progression of polycystic kidney disease in bpk mice is relatively complicated, with neonatal treatment being associated with some amelioration of the renal dysfunction and extrarenal pathology without an effect on the renal pathology. Continuation of treatment beyond 9 days increased morbidity. Therefore, in discussing the role of EGF or EGF receptor in mediating the pathophysiology of PKD, the stage of development may be an important consideration.

show abstract

“…During shorter incubation periods (1-12 h) these three agonists did not initiate peri cyte DNA synthesis either (data not shown). Furthermore, insulin with a half-life of 10-30 min [26] and EGF with one of 2-3 min [27] induced pericyte DNA synthesis after a 24-hour incubation, indicating that the stages of the pericyte cell cycle following late G l, S, G2, and M phase appear to proceed indepen dent of external factors as observed in other cell types [28,29], In other words, even though agonists were removed (labile ago nists) from medium, if they are mitogenic to pericytes, e.g., EGF and insulin, pericytes al ready progressed to these later stages can ad vance around the cycle.…”

Section: Discussionmentioning

confidence: 99%

Agonist-Induced Phosphatidylinositide Breakdown and Mitogenesis in Retinal Capillary Pericytes

Luan

Yanoff

1994

Ophthalmic Res

View full text Add to dashboard Cite

We have examined the effects of a variety of vasoactive agents and growth factors on phosphatidylinositide turnover and DNA synthesis in cultured retinal capillary pericytes. A complex correlation between phosphatidylinositide turnover and DNA synthesis varied with different agonists. The resulting data indicate that phosphatidylinositide turnover is not the sole signaling pathway, and there must be multiple signaling pathways involved in pericyte mitogenesis.

show abstract

Comparison of organ uptake and disappearance half-time of human epidermal growth factor and insulin

Cited by 17 publications

References 38 publications

Cell Microenvironment Engineering and Monitoring for Tissue Engineering and Regenerative Medicine: The Recent Advances

Cell Microenvironment Engineering and Monitoring for Tissue Engineering and Regenerative Medicine: The Recent Advances

Renal dysfunction but not cystic change is ameliorated by neonatal epidermal growth factor in bpk mice

Agonist-Induced Phosphatidylinositide Breakdown and Mitogenesis in Retinal Capillary Pericytes

Contact Info

Product

Resources

About